Emerging drugs for non-small-cell lung cancer

Author： Felip Enriqueta   Santarpia Mariacarmela   Rosell Rafael  

Publisher： Informa Healthcare

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.12, Iss.3, 2007-09, pp. : 449-460

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging drugs for non-small cell lung cancer

By Cappuzzo Federico   Bartolini Stefania   Crinò Lucio  

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 1, 2003-05 ,pp. : 179-192

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for small-cell lung cancer

By Metro Giulio   Cappuzzo Federico  

Expert Opinion on Emerging Drugs, Vol. 14, Iss. 4, 2009-12 ,pp. : 591-606

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Gefitinib in Non-Small-Cell Lung Cancer

By Frampton James E.   Easthope Stephanie E.  

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 133-136

Adis International

Access to resources Recommend Favorite

Vandetanib for the treatment of non-small-cell lung cancer

By Wong Hui-li   de Boer Richard H  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 14, 2011-10 ,pp. : 2271-2278

Informa Healthcare

Access to resources Recommend Favorite

DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients

By Nogueira Augusto   Assis Joana   Catarino Raquel   Medeiros Rui  

Pharmacogenomics, Vol. 14, Iss. 6, 2013-04 ,pp. : 689-700

Future Medicine

Access to resources Recommend Favorite